Behavioral effects and anticonvulsant efficacies of low- affinity, uncompetitive NMDA antagonists in mice

Psychopharmacology

Volumn 146, Issue 3, 1999, Pages 280-289

  Geter Douglass, Beth ^a   Witkin, Jeffrey M ^b  

^a NIDA Addiction Research Center   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Convulsion; Discriminative stimulus effect; Locomotor activity; Mice; NMDA antagonist

Indexed keywords

AMANTADINE; DIZOCILPINE; IBOGAINE; ION CHANNEL; MEMANTINE; N METHYL DEXTRO ASPARTIC ACID; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; PHENCYCLIDINE;

ANIMAL BEHAVIOR; ANTICONVULSANT ACTIVITY; ARTICLE; ATAXIA; BINDING AFFINITY; DISCRIMINATIVE STIMULUS; DRUG EFFECT; DRUG EFFICACY; DRUG RECEPTOR BINDING; LOCOMOTION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; ANTICONVULSANTS; DISCRIMINATION LEARNING; DIZOCILPINE MALEATE; DOSE-RESPONSE RELATIONSHIP, DRUG; EXCITATORY AMINO ACID ANTAGONISTS; IBOGAINE; MALE; MEMANTINE; MICE; MOTOR ACTIVITY; RECEPTORS, N-METHYL-D-ASPARTATE;

EID: 0032882035     PISSN: 00333158     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002130051118     Document Type: Article

References (64)

1. Adler CH, Stern MB, Vernon G, Hurtig HI (1997) Amantadine in advanced Parkinson's disease: good use of an old drug. J Neurol 244:336-337
2. Balster RL, Willetts J (1988) Receptor mediation of the discriminative stimulus properties of phencyclidine and sigma-opioid agonists. In: Colpaert FC, Balster RL (eds) Psychopharmacology: transduction mechanisms of drug stimuli, series 4. Springer, Berlin Heidelberg New York, pp 122-135
3. Bubser M, Zadow B, Kronthaler U, Felsheim U, Rückert GH, Schmidt WJ (1997) Behavioural pharmacology of the non-competititve NMDA antagonists dextrorphan and ADCI: relations between locomotor stimulation, anticataleptic potential and forebrain dopamine metabolism. Naunyn Schmiedebergs Arch Pharmacol 355:767-773
4. Baumann MH, Rothman R, Ali SF (1998) Neurochemical and neuroendocrine effects of ibogaine in rats: comparison to MK-801. Ann NY Acad Sci 844:252-264
5. Bresink I, Danysz W, Parsons CG, Mutschler E (1995) Different binding affinities of NMDA receptor channel blockers in various brain regions - indication of NMDA receptor heterogeneity. Neuropharmacology 34:533-540
6. Carter A (1994) Many agents that antagonize the NMDA receptor-channel complex in vivo also cause disturbances of motor co-ordination. J Pharmacol Exp Ther 269:573-580
7. Chen HSV, Pellegrini JW, Aggarwal SK, Lei SZ, Warach S, Jensen FE, Lipton SA (1992) Open-channel block of N-methyl-D-aspartate (NMDA) responses by memantine: therapeutic advantage against NMDA receptor-mediated neurotoxicity. J Neurosci 12:4427-4436
8. Chen K, Kokate TO, Donevan SD, Carroll FI, Rogawski MA (1996) Ibogaine block of the NMDA receptor: in vitro and in vivo studies. Neuropharmacology 35:423-431
9. Danysz W, Parsons CO, Kornhuber J, Schmidt WJ, Quack G (1997) Aminoadamantanes as NMDA receptor antagonists and antiparkinsonian agents-preclinical studies. Neurosci Biobehav Rev 21:455-468
10. Geter-Douglass B, Witkin JM (1997) Dizocilpine-like discriminative stimulus effects of competitive NMDA receptor antagonists. Psychopharmacology 133:43-50
11. Ginski M, Witkin JM (1994) Sensitive and rapid behavioral differentiation of N-methyl-D-aspartate receptor antagonists. Psychopharmacology 114:573-582
12. Glick SD, Maisonneuve IS (1998) Mechanisms of antiaddictive actions of ibogaine. Ann NY Acad Sci 844:214-226
13. Glick SD, Rossman K, Steindorf S, Maisonneuve IM, Carlson JN (1991) Effects and aftereffects of ibogaine on morphine self-administration in rats. Eur J Pharmacol 195:341-345
14. Glick SD, Rossman K, Rao NC, Maisonneuve IM, Carlson JN (1992) Effects of ibogaine on acute signs of morphine withdrawal in rats: independence from tremor. Neuropharmacology 31:497-500
15. Glick SD, Kuehne ME, Raucci J, Wilson TE, Larson D, Keller RW, Carlson JN (1994) Effects of iboga alkaloids on morphine and cocaine self-administration in rats: relationship to tremorigenic effects and to effects on dopamine release in nucleus accumbens and striatum. Brain Res 657:14-22
16. Grant KA, Snell LD, Rogawski MA, Thurkauf A, Tabakoff B (1992) Comparison of the effects of the uncompetitive N-methyl-D-aspartate antagonist (±)-5-aminocarbonyl-10,11-dihydro-5h-dibenzo[a,d]cyclohepten-5,10-imine (ADCI) with its structural analogs dizocilpine (MK-801) and carbamazepine on ethanol withdrawal seizures. J Pharmacol Exp Ther 269:1017-1022
17. Grant KA, Colombo G, Grant J, Rogawski MA (1996) Dizocilpine-like discriminative stimulus effects of low-affinity un-competitive NMDA antagonists. Neuropharmacology 35:1709-1719
18. Helsley S, Filipink RA, Bowen WD, Rabin RA, Winter JC (1998) The effects of sigma, PCP, and opiate receptor ligands in rats trained with ibogaine as a discriminative stimulus. Pharmacol Biochem Behav 59:495-503
19. Itzhak Y, Ali SF (1998) Effect of ibogaine on the various sites of the NMDA receptor complex and sigma binding sites in rat brain. Ann NY Acad Sci 844:245-251
20. Jones HE, Li H, Balster RL (1998) Failure of ibogaine to produce phencyclidine-like discriminative stimulus effects in rats and monkeys. Pharmacol Biochem Behav 59:413-418
21. Koek W. Colpaert FC (1990) Selective blockade of N-methyl-D-aspartate (NMDA)-induced convulsions by the NMDA antagonists and putative glycine antagonists: relationships with phencyclidine-like behavioral effects. J Pharmacol Exp Ther 252:349-357
22. Kornhuber J, Quack G (1995) Cerebrospinal fluid and serum concentrations of the N-methyl-D-aspartate (NMDA) receptor antagonist memantine in man. Neurosci Lett 195:137-139
23. Kornhuber J, Weller M (1993) Amantadine and the glutamate hypothesis of schizophrenia: experiences in the treatment of neuroleptic malignant syndrome. J Neural Transm 92:57-65
24. Kornhuber J, Bormann J. Retz W, Hübers M, Riederer P (1989) Memantine displaces [3H]MK-801 at therapeutic concentrations in post-mortem human frontal cortex. Eur J Pharmacol 166:589-590
25. Kornhuber J, Bormann J, Hübers M, Rusche K, Riederer P (1991) Effects of the 1-amino-adamantanes at the MK-801 site of the NMDA receptor-gated ion channel: a human postmortem brain study. Eur J Pharmacol 206:297-300
26. Kornhuber J, Weller M, Schoppmeyer K, Riederer P (1994) Amantadine and memantine are NMDA receptor antagonists with neuroprotective properties. J Neural Transm Suppl 43:91-104
27. Kornhuber J. Quack G. Danysz K, Jellinger K, Danielczyk W, Gsell W, Reiderer P (1995) Therapeutic brain concentration of the NMDA receptor antagonist amantadine. Neuropharmacology 34:713-721
28. Krystal JH, Karper LP, Seibyl JP, Freeman GK, Delaney R, Bremner JD, Heninger GR, Bowers MB, Charney DS (1994) Subanesthetic effects of the non-competitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch Gen Psychiatry 51:199-214
29. Leander JD, Lawson RR, Ornstein PL, Zimmerman DM (1988) N-methyl-D-aspartic acid-induced lethality in mice: selective antagonism by phencyclidine-like drugs. Brain Res 448:115-120
30. Leppik IE, Marienau K, Graves NM, Rask CA (1988) MK-801 for epilepsy: a pilot study. Neurology 38:405
31. Litchfield JT, Wilcoxon F (1949) A simplified method for evaluating dose-effect experiments. J Pharmacol Exp Ther 96:99-113
32. Luxton T, Parker LA, Siegel S (1996) Ibogaine fails to interrupt the expression of a previously established one-trial morphine place preference. Prog Neuropsychopharmacol Biol Psychiatry 20:857-872
33. Mash DC, Kovera CA, Buck BE, Norenberg MD, Shapshak P, Hearn WL, Sanchez-Ramos J (1998) Medication development of ibogaine as a pharmacotherapy for drug dependence. Ann NY Acad Sci 844:274-292
34. Monn JA, Thurkauf A, Mattson MV, Jacobson AE, Rice KC (1990) Synthesis and structure-activity relationship of C5-substituted analogues of (±)-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5,10-imine[(+)-desmethyl-MK8 01]: ligands for the NMDA receptor-coupled phencyclidine binding site. J Med Chem 33:1069-1076
35. Muir KW, Lees KR (1995) Clinical experience with excitatory amino acid antagonist drugs. Stroke 26:503-513
36. USDHHS (1994) National household survey on drug abuse: main findings 1994. Office of Applied Studies, Substance Abuse and Mental Health Services Administration, US Department of Health and Human Services, Public Health Service
37. Nicholson KL, Jones HE, Balster R1 (1998) Evaluation of the reinforcing and discriminative stimulus properties of the low-affinity N-methyl-D-aspartate channel blocker memantine. Behav Pharmacol 9:231-243
38. Parker LA, Luxton T, Siegel S (1995) Ibogaine attenuates morphine-induced conditioned place preference. Exp Clin Psychopharmacol 3:344-348
39. Parsons CG, Quack G, Bresink I, Baran L, Przegalinski E, Kostowski W, Krzascik P, Hartmann S, Danysz W (1995) Comparison of the potency, kinetics and voltage-dependency of a series of uncompetitive NMDA receptor antagonists in vitro with anticonvulsive and motor impairment activity in vivo. Neuropharmacology 34:1239-1258
40. Parsons CG, Danysz W, Quack G (1998) Glutamate in CNS disorders as a target for drug development: an update. Drug News Perspect 11:523-569
41. Popik P, Danysz W (1997) Inhibition of reinforcing effects of morphine and motivational aspects of naloxone-precipitated opioid withdrawal by N-methyl-D-aspartate receptor antagonist, memantine. J Pharmacol Exp Ther 280:854-865
42. Popik P. Skolnick P (1996) The NMDA antagonist memantine blocks the expression and maintenance of morphine dependence. Pharmacol Biochem Behav 53:791-797
43. Popik P, Layer RT, Skolnick P (1994) The putative anti-addictive drug ibogaine is a competitive inhibitor of [3H]MK-801 binding to the NMDA receptor complex. Psychopharmacology 114:672-674
44. Popik P, Layer RT, Skolnick P (1995a) One hundred years of ibogaine: neurochemical and pharmacological actions of a putative anti-addictive drug. Pharmacol Rev 47:235-253
45. Popik P, Layer RT, Fossom LH, Benveniste M, Geter-Douglass B, Witkin JM, Skolnick P (1995b) NMDA antagonist properties of the putative antiaddictive drug ibogaine. J Pharmacol Exp Ther 275:753-760
46. Porter RH, Greenamyre JT (1995) Regional variations in the pharmacology of NMDA receptor channel blockers: implications for therapeutic potential. J Neurochem 64:614-623
47. Rabey JM, Nissipeanu P, Korczyn AD (1992) Efficacy of memantine, an NMDA receptor antagonist, in the treatment of Parkinson's disease. J Neural Transm 4:277-282
48. Riederer P, Lange KW, Kornhuber J, Danielczyk W (1991) Pharmacotoxic psychosis after memantine in Parkinson's disease. Lancet 338:1022-1023
49. Roberts J, Porter RHP (1995) Characterization and modulation of binding to the glutamate receptor. In: Stone TW (ed) CNS neurotransmitters and neuromodulators: glutamate. CRC Press, Boca Raton, pp 66-82
50. Rogawski MA (1993) Therapeutic potential of excitatory amino acid antagonists: channel blockers and 2,3-benzodiazepines. Trends Pharmacol Sci 14:325-331
51. Rogawski MA, Yamaguchi S-I, Jones SM, Rice KC, Thurkauf A, Monn JA (1991) Anticonvulsant activity of the low-affinity uncompetitive N-methyl-D-aspartate antagonist (±)-5-amino-carbonyl-10,11-dihydro-5h-dibenzo[a,d]cyclohepten-5,10-imine (ADCI): comparison with the structural analogs dizocilpine (MK-801) and carbamazepine. J Pharmacol Exp Ther 259:30-37
52. Rogawski MA, Yamaguchi S, Blake PA, Jones SM, Bieda Mc, de Costa BR, Thurkhauf A (1992) Anticonvulsant 1-phenylcycloalkylamine analogs: uncompetitive NMDA antagonists with low motor toxicity. In: Kamenka J-M, Domino EF (eds) Multiple sigma and PCP receptor ligands: mechanisms for neuromodulation and neuroprotection? NPP Books, Ann Arbor, MI, pp 747-758
53. Sanger DJ, Zivkovic B (1989) The discriminative stimulus effects of MK-801 generalization to other N-methyl-D-aspartate receptor antagonists. J Psychopharmacol 3:198-204
54. Sanger DJ, Terry P, Katz JL (1992) Memantine has phencyclidine-like but not cocaine-like discriminative stimulus effects in rats. Behav Pharmacol 3:265-268
55. Seidleck BK, Thurkauf A, Witkin JM (1994) Evaluation of ADCI against convulsant and locomotor stimulant effects of cocaine: comparison with the structural analogs, dizocilpine and carbamazepine. Pharmacol Biochem Behav 47:839-844
56. Sershen H, Hashim A, Lajtha A (1994) Ibogaine reduces preferences for cocaine consumption in C57BL/6By mice. Pharmacol Biochem Behav 47:13-19
57. Snyder SH (1980) Phencyclidine. Nature 285:355-356
58. Touchette N (1993) Ibogaine neurotoxicity raises new questions in addiction research. J NIH Res 5:50-55
59. Tricklebank MD, Singh L, Dies RJ, Preston C, Iversen SD (1989) The behavioural effects of MK-801: a comparison with antagonists acting non-competitively and competitively at the NMDA receptor. Eur J Pharmacol 167:127-135
60. Troupin AS, Mendius JR, Cheng F, Risinger MW (1986) MK-801. In: Meldrum BS, Porter RJ (eds) New anticonvulsant drugs. John Libbey, London, pp 191-201
61. Willetts J, Balster RL, Leander JD (1990) The behavioral pharmacology of NMDA receptor antagonists. In: Lodge D, Collingridge GL (eds) The pharmacology of excitatory amino acids. Elsevier, Cambridge, pp 62-67
62. Witkin JM (1995) Role of NMDA receptor in behavior and behavioral effects of drugs. In: Stone TW (ed) CNS neurotransmitters and neuromodulators: glutamate. CRS Press, Boca Raton, pp 323-350
63. Witkin JM, Gasior M, Heifets B, Tortella FC (1999) Anticonvulsant efficacy of N-methyl-D-aspartate antagonists against convulsions induced by cocaine. J Pharmacol Exp Ther 289:703-711
64. Wong EHF, Knight AR, Woodruff GN (1988) [3H]MK-801 labels a site on the N-methyl-D-aspartate receptor channel complex in rat brain membranes. J Neurochem 50:274-228